134,374 Shares in Omnicell, Inc. (NASDAQ:OMCL) Acquired by Pier Capital LLC

Pier Capital LLC acquired a new stake in shares of Omnicell, Inc. (NASDAQ:OMCL) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 134,374 shares of the company’s stock, valued at approximately $5,859,000. Pier Capital LLC owned about 0.29% of Omnicell at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. Pacer Advisors Inc. raised its position in shares of Omnicell by 32.6% in the 2nd quarter. Pacer Advisors Inc. now owns 2,070,434 shares of the company’s stock worth $56,047,000 after purchasing an additional 508,789 shares during the last quarter. Dimensional Fund Advisors LP increased its stake in Omnicell by 0.3% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,180,503 shares of the company’s stock valued at $31,955,000 after purchasing an additional 3,570 shares in the last quarter. Victory Capital Management Inc. raised its holdings in Omnicell by 11,982.3% in the third quarter. Victory Capital Management Inc. now owns 1,148,426 shares of the company’s stock worth $50,071,000 after buying an additional 1,138,921 shares during the last quarter. ArrowMark Colorado Holdings LLC lifted its stake in shares of Omnicell by 27.1% in the third quarter. ArrowMark Colorado Holdings LLC now owns 1,140,873 shares of the company’s stock worth $49,742,000 after buying an additional 243,353 shares in the last quarter. Finally, Federated Hermes Inc. grew its holdings in shares of Omnicell by 1,113.6% during the second quarter. Federated Hermes Inc. now owns 991,151 shares of the company’s stock valued at $26,830,000 after buying an additional 909,480 shares during the last quarter. 97.70% of the stock is owned by institutional investors.

Omnicell Stock Performance

OMCL stock opened at $46.00 on Friday. The business’s 50-day moving average is $44.90 and its two-hundred day moving average is $38.54. The company has a market cap of $2.13 billion, a price-to-earnings ratio of -117.95, a P/E/G ratio of 34.89 and a beta of 0.77. Omnicell, Inc. has a fifty-two week low of $25.12 and a fifty-two week high of $55.74.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on the stock. JPMorgan Chase & Co. boosted their price objective on shares of Omnicell from $37.00 to $44.00 and gave the stock a “neutral” rating in a report on Thursday, November 21st. Wells Fargo & Company boosted their price target on Omnicell from $30.00 to $41.00 and gave the stock an “equal weight” rating in a research note on Monday, October 14th. Craig Hallum increased their price objective on Omnicell from $45.00 to $64.00 and gave the company a “buy” rating in a research report on Thursday, October 31st. Barclays boosted their target price on Omnicell from $39.00 to $58.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 31st. Finally, Benchmark reaffirmed a “buy” rating and set a $48.00 price target on shares of Omnicell in a report on Wednesday, October 9th. Five analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat, Omnicell presently has an average rating of “Hold” and an average target price of $52.00.

Omnicell Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.